JPMorgan Chase & Co. Reiterates Neutral Rating for Teva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA)‘s stock had its “neutral” rating restated by equities researchers at JPMorgan Chase & Co. in a research report issued on Tuesday. They currently have a $56.00 price objective on the stock, up from their previous price objective of $55.00. JPMorgan Chase & Co.’s price target points to a potential upside of 9.55% from the company’s current price.
A number of other analysts have also recently weighed in on TEVA. Analysts at Argus upgraded shares of Teva Pharmaceutical Industries Ltd from a “hold” rating to a “buy” rating in a research note on Friday. They now have a $58.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Monday, June 2nd. They now have a $53.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Friday, May 16th. They now have a $61.00 price target on the stock. Nine analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries Ltd currently has an average rating of “Buy” and a consensus target price of $56.41.
Shares of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) traded up 0.47% during mid-day trading on Tuesday, hitting $51.36. The stock had a trading volume of 1,307,435 shares. Teva Pharmaceutical Industries Ltd has a one year low of $36.26 and a one year high of $54.70. The stock has a 50-day moving average of $50.43 and a 200-day moving average of $46.58. The company has a market cap of $43.692 billion and a P/E ratio of 31.58.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last issued its quarterly earnings data on Thursday, May 1st. The company reported $1.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.22. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $5.11 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. The company’s revenue for the quarter was up 2.0% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Ltd will post $4.71 EPS for the current fiscal year.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is an Israel-based pharmaceutical and drug company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.